Bardoxolone meets primary goal in CKD study

Reata Pharmaceuticals Inc. (Irving, Texas) and partner Abbott Laboratories (NYSE:ABT) said once-daily bardoxolone methyl met the primary endpoint vs. placebo in a Phase IIb trial to treat chronic kidney disease (CKD) in patients with Type II diabetes. Bardoxolone significantly increased mean estimated glomerular filtration rate (eGFR) from baseline to week 24 vs. placebo (10.1 vs. 0.1 mL/min/1.73 m2, p<0.0001). Data were presented at the American Society of Nephrology meeting in Denver. ...